RT Journal Article
SR Electronic
T1 High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.30.20165027
DO 10.1101/2020.07.30.20165027
A1 Macías, Juan
A1 Pinilla, Ana
A1 Lao-Dominguez, Francisco A.
A1 Corma, Anaïs
A1 Contreras-Macias, Enrique
A1 González-Serna, Alejandro
A1 Gutierrez-Pizarraya, Antonio
A1 Fernández-Fuertes, Marta
A1 Morillo-Verdugo, Ramón
A1 Trigo, Marta
A1 Real, Luis M.
A1 Pineda, Juan A.
YR 2020
UL http://medrxiv.org/content/early/2020/08/01/2020.07.30.20165027.abstract
AB The impact of drug-drug interactions (DDI) between ritonavir-boosted lopinavir (LPV-r) to treat patients with coronavirus disease 2019 (COVID-19) and commonly used drugs in clinical practice is not well-known. Thus, we evaluated the rate and severity of DDI between LPV-r for COVID-19 treatment and concomitant medications. This was a cross-sectional study including all individuals diagnosed of SARS-CoV-2 infection treated with LPV-r and attended at a single center in Southern Spain (March 1st to April 30th, 2020). The frequency [95% confidence interval (95% CI)] of potential and major DDI were calculated. Overall, 469 patients were diagnosed of COVID-19, 125 (27%) of them were prescribed LPV-r. LPV-r had potential DDI with concomitant medications in 97 (78%, 95% CI: 69%-85%) patients, and in 33 (26%, 95% CI: 19%-35%) individuals showed major DDI. Twelve (36%) patients with major DDI and 14 (15%) individuals without major DDI died (p=0.010). After adjustment, only the Charlson index was independently associated with death [adjusted OR (95% CI) for Charlson index ≥5: 85 (10-731), p <0.001]. LPV-r was discontinued due to side effects in 31 (25%) patients. Management by the Infectious Diseases Unit was associated with a lower likelihood of major DDI [adjusted odds ratio (95% CI): 0.14 (0.04-0.53), p=0.003). In conclusion, a high frequency of DDI between LPV-r for treating COVID-19 and concomitant medications was found, including major DDI. Patients with major DDI showed worse outcomes, but this association was explained by the older age and comorbidities. Patients managed by the Infectious Diseases Unit had lower risk of major DDI.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study has not been fundedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was designed and performed according to the Helsinki declaration and approved by the Ethics Committee of the Valme University Hospital (Seville, Spain). Informed consent was waived by the Ethics Committee of the Valme University Hospital due to the observational retrospective design of the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is reported in the paper